BNT162b2 mRNA COVID-19 Vaccine: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Beatrix Zheng and Version 1 by Hiroyuki Naruse.

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a widespread impact on health, including a substantial mortality among patients with various pre-existing health conditions. Patients with cardiovascular disease (CVD) are more susceptible to the development of severe COVID-19 infection. The incidence of mechanical complications of acute coronary syndrome (ACS) increased fivefold after the declaration of a state of emergency in Japan. Therefore, vaccination against SARS-CoV-2 is generally recommended in patients with CVD, as is vaccination against other infectious agents. The BNT162b2 mRNA COVID-19 vaccine has shown promising efficacy and safety, mainly in people without apparent pre-existing comorbidities. A nationwide mass vaccination study focused on the estimated vaccine effectiveness of patients with various comorbidities such as heart disease. No data, however, are available regarding the vaccine effectiveness in patients with CVD alone. So it's necessary to investigate the humoral response of patients with CVD to the BNT162b2 mRNA COVID-19 vaccine compared to that in healthcare workers (HCWs).

  • coronavirus disease 2019 (COVID-19)
  • vaccine
  • cardiovascular disease
  • immunogenicity

1. Analysis on Results

1.1. Baseline Characteristics of the Study Participants

The demographics and clinical characteristics of the participants are summarized in Table 1. A total of 264 participants were enrolled in this study: 85 patients with CVD (median (interquartile range) age, 74 (68–77) years; 67 men) and 179 HCWs (49 (41–55) years; 58 men). Among patients, the most common diagnosis was coronary artery disease (53 patients (63%)), followed by arrhythmia (9 patients (11%)) and hypertensive heart disease (10 patients (12%)). Intervals between the first and second dose of vaccinations and serum sampling were comparable between patients (14.7 ± 1.9, 14.9 ± 1.7 days) and HCWs (14.7 ± 1.7, 14.3 ± 1.6 days).
Table 1. Baseline characteristics of the study participants.
  Patients (n = 85) HCWs (
Variablesn = 179)
Univariable Analysis Multivariable Analysis
  β Coefficient 95% CI p Value β Coefficient 95% CI
Age, y 74 (68–77) 49 (41–55)
Male 67 (79) 58 (32)
8 (9)
Statins
46 (54)
Antiplatelet drugs
37 (44)
Anticoagulant drugs
16 (19)
Intervals between the first vaccination and sampling, day
14.7 ± 1.9
14.7 ± 1.7
Intervals between the second vaccination and sampling, day 14.9 ± 1.7 14.3 ± 1.6
Data are expressed as median (25th–75th percentile), number (%), or mean ± standard deviation. NA, not applicable. HCWs, healthcare workers; AF, atrial fibrillation; RAAS, renin–angiotensin–aldosterone system.

1.2. Seropositivity after Vaccination

Among all participants, 188 (71%) were seropositive for RBD−IgG (>0.86 U/mL) at 14 days after the prime dose. The prevalence of seropositivity in patients with CVD after the prime dose was significantly lower compared to that of HCWs (21% vs. 95%, p < 0.001). After adjusting for covariables, patients with CVD (compared to HCWs) were associated with a low positive serological response (Table 2). All participants had developed a positive antibody response by 14 days after the booster dose.
Table 2. Multivariable logistic analysis of seropositive status after first vaccination.
Variables Univariable Analysis Multivariable Analysis
  Odds Ratio 95% CI p Value Odds Ratio 95% CI p Value
p Value
Patients with CVD (vs. HCWs) 0.01 0.01 to 0.03 <0.001 0.08 0.02 to 0.33 <0.001
Patients with CVD (vs. HCWs) −0.22 −0.34 to −0.10 <0.001 −0.32 −0.60 to −0.04 0.02
Age (per 1 year increment) 0.86 0.82 to 0.89 <0.001 0.95 0.90 to 0.99
Age (per 1 year increment)0.02 −0.14 −0.27 to −0.02 0.03 0.12 −0.08 to 0.31 0.25 Hypertension 56 (66) 16 (9)
Male 0.19 0.10 to 0.34 <0.001 0.78 0.30 to 2.00
Male0.61 −0.22 −0.34 to −0.10 <0.001 −0.17 −0.30 to −0.03 0.02 Dyslipidemia 58 (68) 5 (3)
Allergic disease 5.33 2.58 to 11.0 <0.001 1.16 0.39 to 3.45 0.79 Diabetes 26 (31) 1 (1)
Hypertension <0.001 0.60 0.21 to 1.74Allergic disease 8 (9) 86 (48)
0.35
Dyslipidemia 0.05 0.03 to 0.10 <0.001 0.88 0.26 to 2.95 0.84 Diagnosis
Diabetes 0.07 0.02 to 0.19 <0.001 0.63 0.19 to 2.10 0.45 Coronary artery disease 53 (63) NA
Arrhythmia 9 (11)
Hypertensive heart disease 10 (12)
0.09 Cardiomyopathy 6 (7)
Aortic dissection or aneurysm 4 (5)
Multivariate model adjusted for all baseline variables with p < 0.05 by univariate analysis. CI, confidence interval; CVD, cardiovascular disease; HCWs, healthcare workers.

1.3. Antibody Titers after Vaccination 

1.3. Antibody Titers after Vaccination

RBD−IgG titers at 14 days after the prime and booster doses increased compared with pre-vaccination and dramatically increased after the booster dose in both the patient and HCW groups (Figure 1). Median RBD−IgG titers at 14 days after the booster were significantly lower in patients with CVD than in HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In a multivariable regression analysis, there was a significant association between patients with CVD (compared to HCWs) and low RBD−IgG titers after the booster dose (Table 3).
Jcm 10 05498 g001 550
Figure 1. Distribution of antibody titer. Humoral quantitative IgG against SARS-CoV-2 spike RBD response at before vaccination, after the first and the second of vaccination in patients with CVD (red box) and in HCWs (blue box). The dots depict antibody levels. A box represents interquartile range and a horizontal line in a box represents the median. CVD, cardiovascular disease; HCWs, healthcare workers; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Table 3. Multivariable regression analysis of RBD−IgG titers after a complete cycle of vaccination.
Hypertension
−0.21 −0.33 to −0.08 0.001 −0.17 −0.34 to 0.01 0.06
Dyslipidemia −0.14 −0.26 to −0.01 0.03 0.17 −0.03 to 0.38 0.10
Diabetes −0.14 −0.26 to −0.01 0.03 −0.04 −0.18 to 0.10 0.60
Valvular disease
3 (4)
0.05 to 0.16
Previous myocardial infarction 26 (31)
Previous coronary revascularization 38 (45)
Paroxysmal or persistent AF 12 (14)
Medications
RAAS inhibitors 41 (48) NA
Beta-blockers 34 (40)
Diuretics
Multivariate model adjusted for all baseline variables with p < 0.05 by univariate analysis. CI, confidence interval; CVD, cardiovascular disease; HCWs, healthcare workers.

 

2. Current Insights on BNT162b2 mRNA COVID-19 Vaccine

Impaired immunogenicity of the BNT162b2 mRNA COVID-19 vaccine has been reported in immunocompromised patients treated for solid tumors [8][1] and with solid organ transplantation [9,10,11][2][3][4]. However, the efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with heart disease has never been investigated. To the best of our knowledge, this is the first study to document a blunt response after a complete cycle of the BNT162b2 mRNA COVID-19 vaccine in patients with CVD.
COVID-19 vaccines demonstrate excellent efficacy in clinical trials [4,5][5][6] and effectiveness in real-world data [6][7], but some individuals still become infected with SARS-CoV-2 after vaccination. A recent study demonstrated that in older adults (≥60 years) who had received their first vaccine dose but not their second, heart disease was associated with post-vaccination infection [12][8]. Our data showed an inferior serological response to the COVID-19 vaccine after the first vaccine dose, which may be associated with susceptibility to COVID-19 infection after vaccination in patients with heart disease. Therefore, these patients may be highly recommended to receive the complete cycle of the COVID-19 vaccine. Hall et al. reported an increment in the immunogenicity of the COVID-19 vaccine with administration of a third dose in transplant recipients [13][9]. Our results demonstrated that patients with CVD had lower antibody levels after a booster dose compared to HCWs, suggesting that these patients should be prioritized to receive the third dose of vaccination.
In this study, differences in age and gender were observed between CVD patients and HCWs. Older age has been repeatedly reported to associate with reduced antibody responses after COVID-19 vaccination [14,15,16][10][11][12]. Female gender has also been shown to correlate with antibody responses to COVID-19 vaccination to various degrees [17][13]. These differences may make it difficult to evaluate the humoral response to COVID-19 vaccination in patients with CVD. In multivariate analyses, however, CVD was independently associated with seropositivity after the first vaccination and RBD−IgG titers after the second vaccination. Furthermore, when we performed multivariate analyses in a subgroup of 16 HCWs over 60 years (median age 65 years; male, 63%) and patients with CVD, similar results were obtained (data not shown). Consequently, we believe that these factors did not significantly affect our results. The mechanisms that emphasize the association between CVD and a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine are still unclear. It is possible that the medications used may be associated with poorer humoral response in patients with CVD. In the present study, there were no significant differences in humoral response according to their medications, such as renin–angiotensin–aldosterone system inhibitors, beta-blockers, and statins. Further investigations are required to clarify this issue.
To date, some COVID-19 vaccines have been approved for emergency use. Diverse platforms have been used to deliver the recombinant SARS-CoV-2 spike, such as mRNA-encapsulating liposomes, adenovirus vectors, and micelle-attached spikes [18][14]. The humoral response may be different according to the type of vaccine. A notable loss of vaccine efficacy against SARS-CoV-2 variants is reported, likely caused by spike mutations in the RBD, N-terminal domain, and other regions [19,20][15][16]. It may be necessary to investigate the neutralizing antibody against variants of SARS-CoV-2.

References

  1. Barrière, J.; Chamorey, E.; Adjtoutah, Z.; Castelnau, O.; Mahamat, A.; Marco, S.; Petit, E.; Leysalle, A.; Raimondi, V.; Carles, M. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann. Oncol. 2021, 32, 1053–1055.
  2. Rabinowich, L.; Grupper, A.; Baruch, R.; Ben-Yehoyada, M.; Halperin, T.; Turner, D.; Katchman, E.; Levi, S.; Houri, I.; Lubezky, N.; et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J. Hepatol. 2021, 75, 435–438.
  3. Schramm, R.; Costard-Jäckle, A.; Rivinius, R.; Fischer, B.; Müller, B.; Boeken, U.; Haneya, A.; Provaznik, Z.; Knabbe, C.; Gummert, J. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients. Clin. Res. Cardiol. 2021, 110, 1142–1149.
  4. Korth, J.; Jahn, M.; Dorsch, O.; Anastasiou, O.E.; Sorge-Hädicke, B.; Eisenberger, U.; Gäckler, A.; Dittmer, U.; Witzke, O.; Wilde, B.; et al. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech). Viruses 2021, 13, 756.
  5. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhartet, S.; Perez, J.L.; Marc, G.P.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615.
  6. Baden, L.R.; Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416.
  7. Dagan, N.; Barda, N.; Kepten, E.; Miron, O.; Perchik, S.; Katzet, M.A.; Hernán, M.A.; Lipsitch, M.; Reis, B.; Balicer, R.D. BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021, 384, 1412–1423.
  8. Antonelli, M.; Penfold, R.S.; Merino, J.; Sudre, C.H.; Molteni, E.; Berry, S.; Canas, L.S.; Graham, M.S.; Klaser, K.; Modat, M.; et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study. Lancet Infect. Dis. 2021, 21, 00460-6.
  9. Hall, V.G.; Ferreira, V.H.; Ku, T.; Ierullo, M.; Majchrzak-Kita, B.; Chaparro, C.; Selzner, N.; Schiff, J.; McDonald, M.; Tomlinson, G.; et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N. Engl. J. Med. 2021, 385, 1244–1246.
  10. Terpos, E.; Trougakos, I.P.; Apostolakou, F.; Charitaki, I.; Sklirou, A.D.; Mavrianou, N.; Papanagnou, E.D.; Liacos, C.I.; Gumeni, S.; Rentziou, G.; et al. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine. Am. J. Hematol. 2021, 96, E257–E259.
  11. Bayart, J.L.; Morimont, L.; Closset, M.; Wieërs, G.; Roy, T.; Gerin, V.; Elsen, M.; Eucher, C.; Van Eeckhoudt, S.; Ausselet, N.; et al. Confounding Factors Influencing the Kinetics and Magnitude of Serological Response Following Administration of BNT162b2. Microorganisms 2021, 9, 1340.
  12. Salvagno, G.L.; Henry, B.M.; Di Piazza, G.; Pighi, L.; De Nitto, S.; Bragantini, D.; Gianfilippi, G.L.; Lippi, G. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics 2021, 11, 832.
  13. Kageyama, T.; Ikeda, K.; Tanaka, S.; Taniguchi, T.; Igari, H.; Onouchi, Y.; Kaneda, A.; Matsushita, K.; Hanaoka, H.; Nakada, T.A.; et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin. Microbiol. Infect. 2021, 21, 00437-7.
  14. Zhang, Y.N.; Paynter, J.; Sou, C.; Fourfouris, T.; Wang, Y.; Abraham, C.; Ngo, T.; Zhang, Y.; He, L.; Zhu, J. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Sci. Adv. 2021, 7, eabj3107.
  15. Tegally, H.; Wilkinson, E.; Giovanetti, M.; Iranzadeh, A.; Fonseca, V.; Giandhari, J.; Doolabh, D.; Pillay, S.; San, E.J.; Msomi, N.; et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 2021, 592, 438–443.
  16. Cherian, S.; Potdar, V.; Jadhav, S.; Yadav, P.; Gupta, N.; Das, M.; Rakshit, P.; Singh, S.; Abraham, P.; Panda, S.; et al. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms 2021, 9, 1542.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Video Production Service
Feedback